Korean Market
EXCH
UNION KOREA PHARM
★

UNION KOREA PHARM Calls Extraordinary General Meeting to Replace Entire Board Under Rehabilitation Plan

 
EXCH
UNION KOREA PHARM
★

Union Korea Pharm Sets Record Date for Extraordinary General Meeting

 
MATR
UNION KOREA PHARM
★★★

Korea Union Pharm Decides to Issue 60 Million Shares at 500 Won to Bukwang Pharm Under Rehabilitation Plan… 75% Dilution Severely Erodes Shareholder Value

 
MATR
UNION KOREA PHARM
★★

Union Korea Pharm Implements 3:1 Reverse Stock Split as Part of Rehabilitation Plan, Delays Listing Date, Existing Shareholders Face Dilution

 
MATR
UNION KOREA PHARM
★★

UNION KOREA PHARM Debt-to-Equity Swap Under Rehabilitation Plan, Existing Shareholders Face Over 650% Dilution

 
OTHR
UNION KOREA PHARM
★

Union Korea Pharm Replaces Entire Board with Bukwang Pharma Nominees Under Rehabilitation Plan

 
EXCH
UNION KOREA PHARM
★

Union Korea Pharm Calls Extraordinary General Meeting for Complete Board Overhaul Under Rehabilitation Plan, Balancing Hope for Normalization with Uncertainty

 
OWNR
UNION KOREA PHARM
★★

Bukwang Pharmaceutical Acquires 60 Million Shares of Union Korea Pharm via Third-Party Allotment, Securing 75.14% Stake, Diluting Existing Shareholders

 
OWNR
UNION KOREA PHARM
★★

Bukwang Pharmaceutical Acquires 60 Million Shares of Union Korea Pharm via Third-Party Allotment, Becoming Largest Shareholder with Massive Dilution Risk

 
EXCH
UNION KOREA PHARM
★

Change of Largest Shareholder to Bukwang Pharmaceutical via Third-Party Allotment under Rehabilitation Plan… Existing Shareholders Diluted by 75%, Short-Term Stock Pressure Expected

 
EXCH
UNION KOREA PHARM
★★★★

Massive third-party allocation capital increase for rehabilitation... risk of 88% dilution for existing shareholders

 
OWNR
UNION KOREA PHARM
★★★★

Park Kwang-seok Acquires 9,455,845 Shares at 500 Won via Debt-to-Equity Swap Under Rehabilitation Plan, Stake at 15.87%: Massive Dilution Threatens Shareholder Value

 
OWNR
UNION KOREA PHARM
★★★★

Park Kwang-seok Acquires 9,455,845 Shares via Debt-to-Equity Swap... Total Shares Surge 7.5-Fold, Severely Diluting Existing Shareholders

 
EXCH
UNION KOREA PHARM
★★★★

UNION KOREA PHARM Extends Trading Suspension Period Due to Capital Reduction and Delisting Risk

 
EXCH
UNION KOREA PHARM
★★★★★

Failure to Complete Change Listing After Capital Reduction Triggers Immediate Delisting Risk